Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

ID#: NCT03486067

Age: 18 years - 66+

Gender: All

Healthy Subjects: No

Study Phase: Phase 1

Recruitment Status: Recruiting

Start Date: April 03, 2018

End Date: November 30, 2026

Contact Information:
BMS Study Connect Contact Center www.BMSStudyConnect.com
855-907-3286
First line of the email MUST contain the NCT# and Site #.
Summary: Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple myeloma.
Eligibility:

Inclusion Criteria:

- History of multiple myeloma with relapsed and refractory disease

- Eastern Cooperative Oncology Group Performance Status of 0 or 1

- Must have measurable disease as determined by the central laboratory

Exclusion Criteria:

- Symptomatic central nervous system involvement of multiple myeloma

- Prior autologous stem cell transplant ≤ 3 months prior

- Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 12 months prior

- History of concurrent second cancers requiring active, ongoing systemic treatment Other protocol-defined inclusion/exclusion criteria apply
Find a Clinical Trial